NCI Cancer Genome Atlas Program Tissue Purchase

Award Date 1/25/2010
Last Date To Order 7/31/2015
Shared Ceiling Not listed
Contract Type
Master IDIQ
Predecessor
Not listed
Successors

The National Cancer Institute (NCI) established this master Indefinite Delivery/Indefinite Quantity (IDIQ) contract to support the Cancer Genome Atlas (TCGA) program by procuring clinically annotated biospecimens from multiple research institutions and medical centers. The contract focuses on collecting tissue samples and associated data from various cancer types, including glioblastoma multiforme, lung squamous cell carcinoma, breast ductal carcinoma, colon adenocarcinoma, breast lobular carcinoma, lung adenocarcinoma, stomach adenocarcinoma, and other cancer varieties. This master contract enables NCI to rapidly acquire specialized tissue samples to support comprehensive genomic research aimed at understanding the molecular basis of cancer.

Task orders under this contract are predominantly awarded to academic medical centers, research universities, and specialized medical research organizations across the United States and internationally. The delivery orders typically range from approximately $6,000 to $884,000, with most contracts having an ultimate completion date between 2012 and 2015. Frequently awarded prime contractors include the University of Pittsburgh, Sloan-Kettering Institute for Cancer Research, University of Texas MD Anderson Cancer Center, and Mayo Clinic. Most task orders are firm fixed-price contracts and were funded through the American Recovery and Reinvestment Act (ARRA). The majority of contracts do not have a specific set-aside designation, though a few were reserved for small businesses. Performance locations span academic and medical research institutions in the United States, Canada, Germany, Singapore, Australia, and Poland, reflecting the global collaborative nature of the TCGA program.

Generated 4/17/25, 3:47 AM